Regeneron Sues Biosimilar Maker Over IP Rights Exemption
Regeneron has sued a biosimilar specialist in a London court, arguing that the rival was infringing on its intellectual property rights because its waiver requests to export a drug treating eye...To view the full article, register now.
Already a subscriber? Click here to view full article